article thumbnail

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Digital Health Global

As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development. For more information on SSI Strategy, please visit www.ssistrategy.com.

article thumbnail

The next revolution in the pharmaceutical industry: the transformative potential of AI

Digital Health Global

Among these transformative innovations, artificial intelligence (AI ) stands out as a major force, reshaping the fields of drug discovery , drug development, clinical trials and patient care.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer

Digital Health Global

About Koneksa Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. Koneksa aims to revolutionize treatment effect detection in clinical research and improve patient outcomes.

article thumbnail

Genialis and Debiopharm Set Up Biomarker Discovery Collaboration

Digital Health Global

Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism. Debiopharm’s main activities include drug development, drug manufacturing and digital health investment.

article thumbnail

Teladoc Livongo merger: what went wrong with the 'one-stop shop for virtual care' strategy?

Lloyd Price

As the ability to collect and analyze large amounts of patient data grows, there is a growing opportunity for companies to develop personalized treatments and care plans. This could lead to mergers between companies that specialize in different aspects of personalized medicine, such as data analytics, genomics, and drug development.

article thumbnail

Koneksa Announces Partnership with Beacon Biosignals for Clinical Trial in Sleep and Neurologic Disorders Using EEG Biomarkers

Digital Health Global

We’re on a mission to revolutionize drug development in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights. “The utilization of evidence-based digital biomarkers is the key to transforming healthcare,” said Chris Benko, CEO, Koneksa. “We’re

article thumbnail

Vital Lines September 2023

Redox

Don’t get so immersed in system processing that you overlook data quality and accessibility, says Deloitte’s Cloud Strategy Officer. Read more Patient engagement Pharma falls short of patient-centricity Experts say orphan drug developers need tech infrastructure, policies, and procedures to overcome patients’ distrust.

FHIR 105